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1. Introduction 
The reproductive function in female mammals, unlike that of males, is cyclical in nature. 
Whilst testosterone exerts a wholly negative control, regulation of the ovarian cycle is 
effected through a complex series of positive and negative feedback mechanisms involving 
the ovary, the pituitary and the hypothalamus. Although the role of these feedback 
mechanisms has been known for many years, our knowledge of the detailed workings 
involved continues to expand. Reproductive-axis hormones have proved to be similar in all 
the mammalian species studied to date. The female cycle can generally be divided into the 
follicular, periovulatory (preovulatory and ovulatory) and luteal phases. The pituitary 
hormones – the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone 
(FSH) – remain at basal levels throughout most of the reproductive cycle, due to negative 
regulation by ovarian hormones (mainly estradiol and progesterone; see fig. 1 for additional 
details). The physiological capacity of steroids to control gonadotropin secretion is evident 
in a marked increase in plasma LH and FSH levels after the menopause or following 
ovariectomy. During the preovulatory phase, the estradiol negative feedback switches to 
positive. Major positive actions by estrogens include: a 20- to 50-fold increase in pituitary 
sensitivity to gonadotropin-releasing hormone (GnRH) (Speight et al., 1981); an increase in 
pituitary GnRH receptors, in concert with GnRH (Clayton et al., 1980); an increase in 
progesterone receptors (PR) in both pituitary and hypothalamus (Conneely et al., 1989); 
stimulation of GnRH synthesis and release, resulting in preovulatory GnRH secretion 
(Sarkar et al., 1976); and a drop in GnRH metabolism by pituitary cells (Danforth et al., 
1990). These positive actions of estradiol lead to the appearance of GnRH self-priming. 
GnRH self-priming is an event with a twofold effect: it prompts an exponential increase in 
pituitary responsiveness to GnRH, and it coordinates increased responsiveness with 
enhanced GnRH release, ensuring that both occur at the same time and thus guaranteeing 
preovulatory LH secretion (Fink, 1995). In rats, this self-priming effect has been found to be 
more effective when GnRH pulses occur at hourly intervals (Fink, 1995), a frequency also 
reported to be optimal in monkeys with hypothalamic lesions (Knobil, 1980) and in women 
with idiopathic hypogonadotropic hypogonadism (Crowley et al., 1985). How does GnRH 
come to possess this unique property? Probably because the preovulatory LH surge is 
indispensable for species reproduction, and the fact that a very small amount of GnRH 
induces a disproportionate release of LH makes the process both economic and efficient 
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(Fink, 1995). In conclusion, although the cyclical nature of reproduction has been recognized 
in both humans and animals for centuries, the sequence of events involved has only recently 
become clear, and a number of questions remain unanswered (Schwartz, 2000).  
 
0 14 28
Days
M D P E
Days
LH
FSH
E2
P
Attenuin
IA
IB
Menstrual cycle Estrous cycle
 
Fig. 1. Diagram showing pituitary and ovarian hormone fluctuation during menstrual 
(woman) and estrous (rat) cycles. LH: luteinizing hormone; FSH: follicle-stimulating 
hormone; E2: estradiol; P: progesterone; IA: inhibin A; IB: inhibin B; M: metestrus; D: 
diestrus; P: proestrus; E: estrus. Days of cycle are synchronized with the LH surge (day 14 in 
women and proestrous afternoon in rats). During the menstrual cycle, and shortly after 
functional luteolysis (drop in E2, P and IA) the secretion of FSH increased, stimulating the 
ovaries and inducing follicular recruitment. In the rat, secondary FSH secretion during early 
estrus stimulated the ovaries, similarly inducing follicular recruitment. In both cases, 
increased FSH secretion augmented attenuin bioactivity by stimulating the ovaries (lower 
panels). Attenuin bioactivity prevented premature occurrence of the LH surge (see text for 
additional details). 
One crucial and still-unresolved question is how the negative feedback exerted by estradiol 
suddenly switches to positive, resulting in the preovulatory LH surge. Though this issue has 
been argued back and forth, no agreement has yet been reached. The positive effects of 
estradiol do not all occur at the same time, nor are they present only during preovulatory 
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secretion. For example, the increased steroid-induced pituitary response to GnRH is directly 
linked to steroid levels during the follicular phase (Yen et al., 1972). Moreover, GnRH self-
priming can be observed experimentally long before the LH surge is due (Waring & 
Turgeon, 1980). All this would suggest that steroids have to reach a critical threshold before 
generating any LH surge (de Koning, 1995), or alternatively that some factor is exerting a 
“braking” effect on the estradiol positive feedback (Whitehead, 1990). Studies of in vitro 
fertilization (IVF) methods argue against the idea of a critical level of estradiol (200 pg/ml 
during 36-48 h): reports indicate that in FSH-treated women with multiple follicles able to 
produce supraphysiological levels of estradiol from the beginning of the follicular phase, 
preovulatory LH secretion does not occur prematurely, and when it does appear it is 
diminished (Ferraretti et al., 1983; Glasier et al., 1988; Messinis et al., 1986). High levels of 
steroids are unlikely to inhibit the preovulatory LH surge, and high exogenous doses of 
estradiol are unable to suppress LH secretion in normal menstrual cycles (Messinis & 
Templeton, 1987). There is thus no evidence to support the hypothesis that abnormal 
estradiol levels inhibit preovulatory LH secretion in stimulated cycles; indeed, the evidence 
so far points to the existence of some non-steroidal factor, produced by stimulated ovaries 
and able to suppress steroidal positive feedback. Over recent decades, the search for 
putative new substances secreted by the ovaries has provided new insights into the role of 
the ovaries in gonadotropin secretion. This chapter focuses on the factor known as attenuin 
(Messinis & Templeton, 1989; Sopelak & Hodgen, 1984). 
1.1 Evidence for the existence of attenuin 
The development of IVF methods for addressing infertility in the 1970s and 1980s also shed 
new light on the role of FSH. In addition to its classic functions (stimulation of aromatase 
activity and estradiol secretion in granulosa cells, and participation in follicular selection 
mechanisms), FSH was found to stimulate the production of an ovarian factor with a special 
ability to reduce preovulatory LH secretion in women. The first evidence for an ovarian 
factor that attenuated GnRH-induced LH secretion appeared in the late 70s, when de Jong et 
al. (1979), using bovine follicular fluid (bFF), observed a drop in the responsiveness of rat 
pituitary cells to GnRH. Over the following decade, a number of studies pointed to the 
existence of a non-steroidal ovarian factor that reduced preovulatory LH release when FSH 
was administered during the follicular phase in women (Ferraretti et al., 1983; Messinis & 
Templeton, 1986), monkeys (Littman & Hodgen, 1984; Schenken et al., 1984) and rats 
(Busbridge et al., 1988; Geiger et al., 1980). This factor was called gonadotropin surge-
attenuating factor (GnSAF), gonadotropin surge-inhibiting factor (GnSIF) or simply 
attenuin. In 1984, Schenken et al. demonstrated for the first time a direct effect of FSH on 
gonadotropin secretion, involving one or more ovarian factor(s). Ovarian venous serum 
(OVS) was collected from FSH-treated monkeys before and after aspiration of the right 
ovarian follicle; the left ovarian follicle remained intact. Serum from right ovaries before 
aspirated and from intact left ovaries inhibited GnRH responsiveness in rat pituitary 
cultures, suggesting that exogenous FSH increased OVS concentrations of a non-steroidal 
ovarian factor with gonadotropin-inhibiting activity. The ovarian origin of attenuin was 
confirmed when Fowler et al. (2002), culturing theca, stroma and granulosa cells from cyclic 
women, showed that attenuin bioactivity was present only in granulosa-cell-conditioned 
medium. Use of a superovulated protocol as a model for increased attenuin bioactivity 
posed a number of problems, including elevated peripheral estradiol and inhibin levels 
during gonadotropin administration (de Jong, 1988; Messinis & Templeton, 1988; 
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Muttukrishna et al., 1994), which raised doubts as to the origin of this bioactivity. With 
regard to estradiol, studies carried out in women have proved that effects on LH secretion 
are not due to negative feedback: Messinis et al. (1991, 1993) demonstrated that a single FSH 
injection had dose-dependent suppressive effects on pituitary responsiveness to exogenous 
GnRH pulses. This effect was seen as early as 8 h after FSH administration, although 
circulating estradiol did not increase significantly until at least 24 h after gonadotropin 
administration. Subsequently, this group also concluded that attenuin bioactivity in FSH-
treated women could not be due to an increase in circulating total ┙-inhibin (Messinis et al., 
1991, 1993, 1994, 1996). 
Attenuin bioactivity has so far been found in serum, FF and ovarian extracts from 
superovulated (Fowler et al., 1994a) and cyclic women (Fowler et al., 1995a), in bFF (Van 
Dieten et al., 1999), in porcine FF (pFF; Danforth et al., 1987; Kita et al., 1994), in rat ovarian 
extracts (de Koning et al., 1989) and in rat testicular extracts (Tio et al., 1994). It should be 
stressed that attenuin bioactivity has been observed in human FF (hFF) from women during 
an untreated spontaneous cycle, suggesting that it plays a physiological role as a central 
regulator (Busbridge et al., 1990; Byrne et al., 1993). 
1.2 Current status of attenuin characterization  
In 1987 Danforth et al., using pFF, showed that attenuin bioactivity displayed certain 
characteristics: it was resistant to moderate heating (60 °C for 60 min), fully recoverable 
from an acetone precipitation, and not bound by a heparin/sepharose affinity matrix of the 
sort widely used to isolate inhibin. To date, attempts to characterize attenuin have proved 
relatively unsuccessful. Purification strategies have obtained very small amounts of 
bioactive material and an abundance of different proteins. The fact that the protein is 
present at very low concentrations makes it difficult to use Edman sequencing, leading to a 
whole range of different results. Tio et al. (1994) isolated inhibin and attenuin by high 
performance liquid chromatography from 32 liters of rat Sertoli cell-conditioned medium. 
Both peptides were separated on polyacrylamide gel; however the partial N-terminal 
sequence of the 37 kDa protein with attenuin bioactivity did not match gene and protein 
databases (Genbank and PIR). Subsequently, employing an elegant sequential series of 
purification techniques, Danforth & Cheng (1995) found a 69 kDa monomeric polypeptide in 
pFF that inhibited GnRH-stimulated LH secretion, but partial N-terminal analysis showed 
no homology with other reproductive hormones. Mroueh et al. (1996) also found a protein 
with attenuin bioactivity in hFF, similar to that reported in pFF (63 kDa). However, Pappa et 
al. (1999), starting from the same source (hFF) treated with multiple and complex 
purification techniques, described a protein with a molecular mass of 12.5 kDa. This protein 
was identified by mass spectrometry as a truncated part of the C-terminus of human serum 
albumin (HSA). The next published purification procedure side-stepped serum albumin 
contamination problems by using a serum- and BSA-free granulosa-luteal cell culture 
system (Fowler et al., 2002). The isolated attenuin-bioactivity protein had a molecular 
weight of 60-70 kDa and an isoelectric point (pI) of 5.7-5.8 pH. The internal and N-terminal 
amino acid sequences did not display significant homology with other accessions in the 
protein-sequence database. Attenuin is therefore thought to be a peptide, different from 
inhibin, with a postulated molecular weight which varies from less than 37 kDa (Tio et al., 
1994) to 64-69 kDa (Danforth & Cheng, 1995; Fowler et al., 2002). These differences may 
reflect the presence either of small active subunits or of larger aggregates with or without 
carrier proteins, and may also reflect species differences. Ingeniously, using the expression-
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secretion system of a yeast (Pichia Pastoris GS115), it has proved feasible to produce 
recombinant polypeptides of HSA. Various polypeptides thus obtained were added to rat 
pituitary cultures and only those corresponding to subdomain IIIB (specifically residues 
490-585) presented attenuin bioactivity, while the whole molecule and even the whole 
subdomain IIIB were inactive (Tavoulari et al., 2004). More recently, Karligiotou et al. (2006) 
used the retrotranscriptase-polymerase chain reaction (RT-PCR) technique and appropriate 
primers to amplify different transcripts from HSA gene in granulosa cells. Results showed 
that while all HSA fragments were expressed in the nucleus, only two fragments (the 
promoter and a C-terminal fragment) were expressed in granulosa cell cytoplasm, 
indicating a differential expression of the HSA gene, probably leading to attenuin synthesis. 
Finally, the current attenuin purification strategy involves the use of phage display 
techniques to produce antibodies against partially-purified human-granulosa-luteal cell-
conditioned medium. Three of these antibodies were found to block human attenuin 
bioactivity on GnRH-induced LH secretion from rat pituitary cell cultures. Subsequently, 
these antibodies were used to immunopurify attenuin; the antigen-antibody complexes 
obtained were separated by electrophoresis. Candidate attenuin spots (around 66 kDa and 
pI 5.5-6.0) were excised for peptide mass mapping. The main molecules identified were HSA 
precursor and variants. All these data suggest that attenuin may be a post-translationally 
modified form of serum albumin, or else may be very tightly bound to, and transported by, 
serum albumin (Sorsa-Leslie et al., 2005). 
1.3 Synthesis and secretion pattern of attenuin 
In women, the production of attenuin in the ovarian follicle is clearly related to follicular 
size in both spontaneous and stimulated cycles. FF from follicles smaller than 11 mm 
(stimulated cycles, Fowler et al., 1994b) or 6-8 mm (spontaneous cycles, Fowler et al., 2001) 
has been found to contain the greatest amount of attenuin. In women receiving fertility 
treatment, there is an increase both in the number of follicles and in serum attenuin 
bioactivity with respect to spontaneous cycles (Byrne et al., 1993). Similarly, small follicles in 
pig ovaries contain the highest attenuin concentrations, while bioactivity falls sharply in 
preovulatory follicles (Kita et al., 1994). Thus, medium from granulosa cell cultures showed 
more attenuin bioactivity when these cells were obtained from aspiration of small follicles 
(Seo & Danforth, 1994). All these findings suggest that small and growing follicles are the 
major producers of attenuin. In summary, attenuin levels are highest during the early part 
of the menstrual cycle (days 1 to 8), falling thereafter as follicular size increases, and 
disappearing at the appropriate preovulatory time (Fowler et al., 2003). The corpus luteum 
does not appear to produce attenuin in women, but small developing follicles may produce 
attenuin during the luteal phase (Messinis et al., 1996; fig. 1 lower panel). 
2. Methods of study 
2.1 In vivo 
In the absence of purified bioactive molecule, for the reasons indicated above, the effect of 
attenuin on the LH surge in rats is currently studied using both in vivo and in vitro 
procedures. The in vivo approach consists in administration of exogenous FSH during the 
diestrous phase in cycling rats as a tool to increase the biological activity of endogenous 
attenuin (Geiger et al., 1980; Gordon et al., 2008). In addition to attenuin, FSH also stimulates 
the synthesis and secretion by granulosa cells of a number of steroidal and non-steroidal 
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factors (mainly estradiol and inhibin) that affect pituitary gonadotropin secretion (Arai et al., 
1996; Watanabe et al., 1990). However, this treatment attenuates the magnitude of the 
proestrous afternoon LH surge despite the presence of high circulating levels of estradiol 
(Geiger et al., 1980; Gordon et al., 2008, de Koning et al., 1987; see fig. 2A for additional details).  
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Fig. 2. Schematic representation of current approaches to the study of attenuin effects on 
luteinizing hormone (LH) secretion. GnRH: gonadotropin releasing hormone; E2: 17┚-
estradiol; FSH: follicle-stimulating hormone; hFF: human follicular fluid. A: in vivo. [1] 
Administration of FSH stimulates the synthesis/secretion of ovarian hormones (E2, inhibin 
and attenuin) [2]. Whereas in proestrus inhibin suppresses FSH secretion (Gordon et al., 
2010a, 2010c) and E2 acts on LH secretion in its positive feedback mode [2], attenuin acting 
on gonadotrope membrane receptor [3] results in a reduction of the magnitude of the LH 
surge [4]. B: in vitro. Administration of FSH stimulates follicular growth and recruitment [1]. 
Pooled hFF from women undergoing IVF treatments [5] is submitted to steroid charcoal-
extraction and inhibin immunoprecipitation (Gordon et al., 2010c). Attenuin-containing hFF 
is then added to cultured pituitary cells or fragments [6]. This results in a reduction of 
GnRH-stimulated LH secretion [7]. 
At the same time, the bioactivity of attenuin can be promoted and/or prolonged by 
removing endogenous inhibin and consequently increasing endogenous FSH. One option is 
the neutralization of inhibin’s biological activity by injection of an anti-inhibin serum on 
metestrus that increases FSH serum levels during diestrus and proestrus, induces 
superovulation and again reduces the magnitude of the proestrous afternoon LH surge 
(Ishigame et al., 2004). 
2.2 In vitro 
However, it is difficult to delineate, in vivo, the precise bioactivity of attenuin in the rat 
pituitary using exogenous FSH. Alternatively, attenuin bioactivity can be studied by in vitro 
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procedures, using cultured anterior pituitary cells or pituitary fragments treated with 
murine FF (Busbridge et al., 1990; Fowler & Spears, 2004), pFF (Danforth & Cheng, 1995) or 
hFF from women undergoing IVF treatments (Byrne et al., 1995a, 1996; Fowler & Templeton 
1996) as a source of exogenous attenuin, following steroid and inhibin depletion (see fig. 2B 
for additional details). 
3. Mechanism of attenuin action 
3.1 Background 
Despite considerable research and the availability of improved molecular techniques, little is 
known about how attenuin acts. This section outlines the key findings reported to date. In 
vitro experiments have highlighted the potentiating effects of increased intracellular 
calcium, stimulation of both intracellular GnRH signalling pathways (calcium- and cAMP-
dependent protein kinases, PKC and PKA respectively), as well as progesterone treatment 
on GnRH-induced LH secretion (Kile & Nett, 1994; Sánchez-Criado et al., 2006). A further 
clue regarding the mechanism by which attenuin acts was discovered when, in rat pituitary 
monolayers, GnRH was co-incubated with either estradiol, progesterone, PMA (phorbol 12-
myristate 13-acetate, a stimulator of PKC) or calcium ionophore. All treatments potentiated 
the effects of GnRH on LH synthesis and release, but administration of hFF counteracted the 
enhancing effects of all these compounds, with one exception: the augmentative effect of 
progesterone on GnRH-induced LH synthesis (Cowking et al., 1995). Shortly afterwards, the 
authors found that while progesterone augmented GnRH self-priming in rat pituitary 
monolayers, this secretion was blocked when hFF and the antiprogestagen RU486 were 
added to the medium (Byrne et al., 1995b). All these findings suggest that the mechanism of  
action of attenuin on preovulatory LH secretion might involve the pituitary PR. There is 
considerable evidence, both in vivo and in vitro, to suggest that attenuin has a suppressant 
effect on GnRH self-priming (Byrne et al., 1996; Koppenaal et al., 1992, 1993). This action has 
been shown to be linked to a blockade of GnRH second messenger pathways rather than to 
competition between attenuin and GnRH for GnRH receptors (Fowler et al., 1994c; Tijssen et 
al., 1997). A study by Helder et al. (1997) reported that the unknown attenuin receptor 
located in the gonadotrope membrane might act through the cAMP pathway. It might thus 
be hypothesized that the inhibiting effect of attenuin on LH secretion is exerted through this 
GnRH second pathway. Both hypotheses, i.e. attenuin acting through a GnRH second 
pathway or through the PR, are feasible, since it has been shown that GnRH can activate the 
PR in a ligand-independent manner through the PKA and/or PKC pathways (Garrido-
Gracia et al., 2006; Turgeon & Waring, 1994).  
3.2 The relationship between attenuin and LH release 
A number of published studies report a reduction of the preovulatory LH surge in vivo in 
rats treated with FSH during metestrus and diestrus (Culler, 1992; Geiger et al., 1980; 
Gordon et al., 2008; de Koning et al., 1987; Shuiling et al., 1999). Additionally, this FSH 
treatment in vivo causes an in vitro suppression of GnRH-stimulated LH secretion, GnRH 
self-priming and progesterone-potentiating effect on GnRH-stimulated LH secretion, 
without affecting basal LH levels (Byrne et al., 1996; Gordon et al., 2008; Koppenaal et al., 
1992, 1993). Pace Geiger et al. (1980), the possibility that these effects are produced by an 
increase in estradiol levels can be ruled out, since animals treated with estradiol benzoate 
display greater LH secretion both in vivo and in vitro; more important, FSH plus estradiol-
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injected ovariectomized rats do not display any suppressant effect on LH secretion (Gordon 
et al., 2008). All this proves conclusively that FSH treatment stimulates the production of 
some ovarian factor(s) other than estradiol, that reduces the preovulatory LH surge but not 
basal LH secretion. Subsequent in vitro research has shown that attenuin produces this 
inhibiting effect on pituitary sensitivity to GnRH in a dose-dependent manner: 
administration of different doses of FSH (0.1, 1 and 10 I.U.) caused variable inhibition of LH 
secretion, partially reversed by simultaneous administration of estradiol (Gordon et al., 
2009a). Attenuin would thus appear to bind to its gonadotrope membrane receptor and 
activate a secondary pathway in order to inhibit preovulatory LH secretion (Fowler & 
Templeton, 1996). The potentiating effects of progesterone, 8-bromo cAMP and PMA on 
GnRH-stimulated LH secretion are antagonized in rat hemipituitaries incubated with 
steroid-free bFF (bFF) or with FF from women undergoing a superovulation protocol 
(Cowking et al., 1995; Tijssen et al., 1997). All this suggests that attenuin may exert a 
suppressant effect on the GnRH secondary pathway. Subsequent research has shown that 
neither progesterone, nor GnRH, nor activation of PKA and PKC has any effect on GnRH-
stimulated LH secretion in FSH-treated cyclic rats (Gordon et al., 2008; 2009b), indicating 
that this effect is probably produced downstream of PKA, PKC and progesterone. Given 
these findings, and the fact that attenuin decreases all PR-dependent parameters of LH 
secretion, it may be postulated that this action is exerted through a modification of PR 
expression and/or action (Garrido-Gracia et al., 2007). 
3.3 The relationship between attenuin, PR and LH release 
With regard to the effect of FSH-treatment on PR gene expression in rats, RT-PCR analysis 
has revealed a partial decrease in PR mRNA (Gordon et al., 2008). Nevertheless, 
immunohistochemical examination revealed no difference in the number of PR-positive 
pituitary cells in FSH injected rats (Gordon et al., 2008, 2009b) or rats in which inhibin was 
immunoneutralized; the latter group, however, did not display a similar partial decrease in 
PR mRNA (Gordon et al., 2010a). These differences may be due to different FSH and/or 
attenuin levels between experimental groups. In most species and tissues, PR is expressed 
by a single gene but transcribed into separate mRNAs as two distinct molecular forms, PR-A 
and PR-B. The B (stimulatory) form contains an additional N-terminal sequence and is the 
main transcription factor, while the A form is modulatory of B in nature (Vegeto et al., 1993; 
Wen et al., 1994). For this reason, the present authors decided to analyze two inhibiting 
possibilities: an increase in PR-A and a decrease in PR-B protein levels. While passive 
immunization against inhibin with an anti-inhibin serum attenuated preovulatory LH 
secretion in cyclic rats, pituitary protein levels of both PR isoforms were unaffected by the 
absence of inhibin. This was the first time the two PR isoform protein levels had been 
demonstrated using the western blot technique in rat pituitaries (Gordon et al., 2010a). 
Although attenuin could exert its negative action on LH secretion by several mechanisms, 
the results pointed to a possible involvement of attenuin in post-translational modifications 
of PR, leading to its inactivation. Phosphorylation at serine residues is the most frequent 
post-translational processing event in PR modification (Beck et al., 1992; Takimoto & 
Horwitz, 1993) and is involved in PR-regulated gene transcription (Denner et al., 1990; Faus 
& Haendler, 2006). To explore this question, two studies were carried out: the first sought to 
measure PR phosphorylation levels, while the second aimed to determine the effect of 
phosphatases on pituitary sensitivity to GnRH.  
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Fig. 3. Methods of studying progesterone receptor (PR) phosphorylation in rat 
gonadotropes. Left panel: Immunoreactive products to PR10A9 antibody in the nulei of 
gonadotropes, the only rat pituitary cell expressing PR (Garrido-Gracia et al., 2008). Pituitaries 
were incubated with medium alone (A, DMEM) or progesterone (B). No differences were 
found between the number of PR positive gonadotropes. Immunohistochemical expression of 
phosphorylated PR gonadotropes (C, D) in anterior pituitaries from proestrous rats (Gordon et 
al., 2009b). Immunoreactive products to pSer294 antibody are observed only in gonadotropes 
of pituitaries incubated with progesterone (D). The relative expression of pSer294-positive 
gonadotropes and PR109A9-positive gonadotropes provides an approximation of the PR 
phosphorylation rate. Right panel: PR A and B isoforms and phosphorylated PR-B content in 
pituitaries from proestrous rats incubated either with medium alone (DMEM) or with 
progesterone (P 10-6 M). Only PR-B phosphorylated product is seen in pituitaries incubated 
with progesterone (Gordon et al., 2011).  
In the first study, the PR phosphorylation protocol in pituitaries was optimized by adding 
progesterone to the incubation medium. Subsequently, pituitaries from rats treated with 
FSH or with anti-inhibin serum were immunostained with an antibody that recognizes the 
immunogen corresponding to amino acid residues 288–300 from human PR-B, Ser294 being 
phosphorylated (Clemm et al. 2000). All the experimental groups in which attenuin was 
increased and preovulatory secretion diminished showed a significant drop in the number 
of cells expressing pSer294 (Gordon et al., 2009b, 2010a; fig. 3, left panel).  
The following study analyzed the in vitro effect of calyculin, a potent inhibitor of 
intracellular phosphatases (Condrescu et al. 1999), on GnRH-stimulated LH secretion and 
GnRH self-priming in FSH-treated rats. The results showed that this drug was able, albeit 
partially, to reverse GnRH-stimulated LH secretion in a dose-dependent manner (Gordon et 
al., 2009b). Altogether, these results suggest that the ovarian-dependent inhibitory effect of 
FSH injection on the preovulatory LH secretion in the rat may involve an imbalance 
between the activities of protein kinases and phosphatases, resulting in a dephosphorylation 
of pituitary PR (see fig. 4 for additional details). In the light of previous 
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immunohistochemical data (Gordon et al., 2009b, 2010a; fig. 3, left panel), the preliminary 
results obtained using the western blot technique (Gordon et al., 2011; fig. 3 right panel) 
supported the hypothesis that attenuin produces an inhibiting effect on LH secretion by 
dephosphorylation of pituitary PR. 
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Fig. 4. Proposed effects of attenuin on the LH surge. GnRH: gonadotropin releasing 
hormone; PR-Ser: gonadotrope unphosphorylated progesterone receptor (PR); PR-Ser-PO42-: 
gonadotrope phosphorylated PR. PR can be activated/phosphorylated in a ligand-
dependent (progesterone) or independent (GnRH second pathways) manner. Attenuin 
reduces phosphorylation of Ser (serine) of the immunogen MAPGRS(p)PLATTV located in 
the N-terminal domain of PR-B. Activated PR-B transcribes “priming proteins” resulting in 
GnRH self-priming. This unique property of gonadotropes, together with estradiol 
sensitization of gonadotropes to GnRH, results first in GnRH-stimulated LH secretion and 
finally in the LH surge.  
3.4 The relationship between attenuin and LH synthesis 
The preovulatory secretion of LH is the result not only of increased LH synthesis (Tse et al., 
1993) but also of increased LH secretion by gonadotropes (Ramey et al., 1987). While the 
effects of attenuin on LH secretion have been exhaustively studied, it is not known whether 
attenuin has any effect on LH synthesis. Fowler et al. (1995b), using rat pituitary cultures, 
studied the effects of steroid-free and inhibin-depleted hFF on GnRH- augmented LH 
synthesis and secretion in rat pituitary cultures. Results showed a decrease in both 
parameters, suggesting that this factor reduces pituitary responsiveness to GnRH by 
suppressing both the de novo synthesis and the acute and long term release of LH. However, 
there is no evidence to show how attenuin might effect this suppression. The present 
authors found that the addition of ionomycin (a calcium ionophore) to the incubation 
medium did not result, as expected, in a massive release of LH in pituitaries from FSH-
treated rats. Moreover, no differences were found in LH secretion between calyculin plus 
GnRH and ionomycin, indicating a possible failure in LH synthesis (Gordon et al., 2009b). 
LH pituitary content and LH┚ mRNA expression were therefore evaluated; results showed 
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that FSH treatment decreased pituitary LH content in intact, but not in ovariectomized, rats 
injected with estradiol benzoate, without affecting LH┚ mRNA levels. Altogether, these 
results suggest lower LH synthesis caused by attenuin, potentiating its inhibiting effects on 
LH secretion (Gordon et al., 2009a).  
3.5 The relationship between attenuin, PR and LH synthesis 
To determine whether pituitary PR was involved in LH synthesis inhibition by attenuin, 
cyclic rats were injected with different doses of FSH and progesterone. Results showed that 
while progesterone by itself had no effect (control groups), saturation of PR with the cognate 
ligand reversed the inhibitory effect of attenuin on LH protein levels, although not on LH 
secretion (Gordon et al., 2010b). Apart from these results showing that attenuin probably 
inhibits LH synthesis at post-transcriptional level, little is known about the mechanism 
involved in that inhibition – probably by increasing LH degradation (Kitahara et al., 1990) 
and/or decreasing GnRH-induced LH polypeptide glycosylation (Ramey et al., 1987) – 
except that, as indicated earlier, the inhibitory pathway in LH synthesis involves the 
gonadotrope PR. However, the detailed mechanism underlying the PR-mediated attenuin-
induced inhibition of LH protein levels requires further detailed investigation. Even so, the 
available evidence supports the view of PR as a keystone in the neuroendocrine integrator at 
both hypothalamic and pituitary levels (Levine et al., 2001). In conclusion, it is postulated 
that, just as inhibin controls FSH synthesis and release (Attardi et al., 1991; Scott & Burger 
1981), attenuin reduces proestrous GnRH-dependent LH secretion through a dual 
mechanism of action: inhibition of both LH synthesis and LH release. 
4. The possible physiological role of attenuin 
4.1 Humans  
Menstrual cyclicity in women is highly dependent on positive and negative ovarian 
feedback mechanisms. During the follicular phase of the cycle, estradiol plays a key role in 
the control of both gonadotropins. Together with this steroid, low concentrations of 
circulating progesterone and inhibin B also contribute to the control of LH and FSH 
secretion, respectively. During the luteal phase, both estradiol and progesterone regulate 
secretion of the two gonadotropins, while inhibin A plays a role in FSH secretion. The 
transition from follicular to luteal phase involves a preovulatory secretion of both LH and 
FSH, helped by the estradiol positive mode (fig. 1, left panel). However, the change from 
negative to positive estradiol feedback at some threshold cannot entirely account for the 
change from pituitary insensitivity to the maelstrom of events leading to the LH surge. 
Although the question remains unresolved, there is evidence that estradiol and attenuin 
interact on the pituitary in the context of the positive feedback mechanism. It may be 
assumed that estradiol sensitizes the pituitary to GnRH, while attenuin antagonizes that 
sensitizing effect. Based on existing knowledge regarding attenuin action and its secretion 
pattern, it has been suggested that attenuin activity is greater during the early and 
midfollicular phases and lower both in the late follicular phase and at midcycle. Therefore, 
the pituitary LH response to GnRH is low during the early and midfollicular phase and is 
markedly enhanced during the late follicular phase, triggering the full expression of the 
preovulatory LH surge. According to this hypothesis, the role of attenuin in humans is to 
control the amplitude and not the onset of the LH surge (Messinis et al., 2006). It should be 
highlighted the possible role of attenuin in the polycystic ovary syndrome (PCOS). In PCOS, 
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the mechanism responsible for abnormal gonadotropin secretion (elevated serum LH) has 
not been completely elucidated. One possible etiopathology mechanism is an increased of 
pituitary responsiveness to GnRH, caused by a decreased in attenuin production (Ruiz et al., 
1996). This would offer an explanation for the most common endocrine disease that affects 
ovulation and fertility. At the same time, and once attenuin had been isolated, this peptide 
could be used as a GnRH antagonist and as a physiological contraceptive agent. 
4.2 Rats 
Administration of FSH during the diestrous phase prompts a reduction in proestrous LH 
secretion in the rat. It is worth noting that the effects of attenuin on proestrus can only be 
observed with this treatment (Culler, 1992; Geiger et al., 1980; Koppenaal et al., 1991). 
However, it is difficult to determine with any precision the role of attenuin in physiological 
conditions using this experimental model. Previous findings by the present authors (Gordon 
et al., 2010c) give grounds for speculation regarding the possible physiological role of 
attenuin. The incubation protocol for pituitary glands from intact cycling rats on each of the 
4 days of the estrous cycle demonstrated the existence of GnRH self-priming in diestrous 
and proestrous phases. Subsequently, steroid-free inhibin-depeleted hFF was added to the 
medium. Results reported by Fowler et al. (Fowler et al., 1994b, 2001, 2003) suggest a 
reduction in attenuin synthesis and/or secretion when the ovarian follicle is close to 
preovulatory size. For this reason, we used hFF from follicles of two sizes: small (<15 mm in 
diameter) and large (>15 mm in diameter). Surprisingly, results in terms of secretion levels 
showed that only diestrous GnRH self-priming, but not proestrous self-priming as expected 
from the effects of injected FSH, was susceptible to the inhibiting action of attenuin 
contained in hFF. It should be noted that hFF from both large and small follicles had the 
same effects on all the LH and FSH secretion parameters so far studied. Nevertheless, the 
possibility that a different inhibitory bioactivity of hFF may be found using hFF from 
smaller follicles cannot be ruled out (Fowler et al., 2003; Fowler & Spears, 2004). Overall, 
these facts were interpreted as signifying that, during the normal estrous cycle, ovarian 
attenuin inhibited pituitary PR-dependent GnRH self-priming in diestrus only. Later on, in 
proestrus, pituitaries become either desensitized to the inhibitory bioactivity of attenuin 
and/or sensitized to the stimulatory activity of GnRH (fig. 1, right panel). By contrast, 
Tijssen et al. (1997) showed that attenuin was able to suppress both diestrous and proestrous 
GnRH self-priming. These discrepancies may be due to the different origins of FF (human 
vs. bovine), to the experimental model used (static vs. dynamic incubation) and to the 
absence or presence of inhibin. Previous results published by this research group (Tébar et 
al., 1996, 1998) support the hypothesis that the pituitary loses sensitivity to attenuin when 
follicles reach the preovulatory size, which would account for estradiol suddenly exerting a 
positive feedback. This intriguing mechanism, by which pituitaries become insensitive to 
attenuin and/or sensitive to the stimulatory action of GnRH, may provide an extra clue for 
understanding estrous cycle length regulation. This factor would limit the physiological 
timing (proestrous afternoon) as well as the magnitude (preovulatory secretion) of pituitary 
responsiveness to GnRH. This research thus shows how a decrease in endogenous FSH 
levels during diestrus, with a consequent reduction in attenuin production but no significant 
effect on estradiol levels, gives rise to a 1- or 2-day advancement of blunted preovulatory 
LH surges in 4- (Tébar et al., 1996, 1998) and 5-day (Sánchez-Criado et al., 1996) cyclic rats, 
respectively. This suggests that, in physiological circumstances, submaximal FSH-
dependent ovarian attenuin bioactivity prevents the premature LH surge in diestrus by 
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antagonizing the secretory effect of GnRH (Koppenaal et al., 1991; Tébar et al., 1998) and/or 
the sensitizing effect of estradiol on the pituitary (Schuiling et al., 1999). On the whole, all 
these findings, together with the existence of pituitary PR on diestrus, would suggest that 
PR-dependent GnRH self-priming in the diestrous phase in the 4-day cyclic rat is blocked by 
attenuin bioactivity. 
5. Conclusions 
Our work over the last few years suggests that attenuin is a FSH-dependent ovarian factor 
different from inhibin, which decreases preovulatory LH secretion in rats by activating 
gonadotrope membrane receptors, resulting in PR dephosphorylation. The reduction in PR 
activity is associated with a decrease in both LH secretion and LH synthesis.  
The bioactivity of attenuin appears to play a major role in synchronizing physiological 
pituitary and ovarian events, so that preovulatory LH secretion is limited to proestrus, when 
the ovarian follicle and the oocyte are in optimal conditions to respond to the LH surge and 
to be fertilized, respectively.  
However, all these findings must be viewed as speculative until experiments can be 
repeated using purified attenuin.  
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